|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer.
|
31470531 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, analyses that considered all 41 genes with clinical variables together identified genes TLR4, BSCL2, CDH1, ERBB2, BRCA2 and SCGB2A1 as independently related to survival in OC.
|
31655274 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
|
31833593 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases.
|
30822630 |
2019 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
|
31328457 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor.
|
30499260 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
In order to assess the validity of ErbB2-targeted therapy in ovarian cancer, we investigated the effectiveness of two FDA-approved tyrosine kinase inhibitors of ErbB2, lapatinib and neratinib, on the growth of ovarian cancers.
|
31689531 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor.
|
31513391 |
2019 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, HER2 protein is over-expressed in epithelial ovarian cancer tissues, and trastuzumab exerts anti-tumor effect by inhibiting cell proliferation and inducing apoptosis, suggesting it might be a novel approach for the treatment of ovarian cancer.
|
30509111 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy.
|
30856589 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.
|
29535531 |
2018 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The data demonstrate that the growth of xenografts of human ovarian cancer with high expression of HER2 could be inhibited effectively by Ad-HER2-siRNA+DDP.
|
30052070 |
2018 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Aberrant <i>EGFR</i> expression and <i>ERBB2/3/4</i> mRNA levels were associated with OC prognosis.
|
30588099 |
2018 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The prognostic role of human epidermal growth factor receptor 2 (HER2) in ovarian cancer has been investigated in previous studies, but the results remain controversial.
|
29381731 |
2018 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 is a member of epidermal factor receptor (EGFR) family which is overexpressed in breast cancer, ovarian cancer and gastric cancer.
|
30225583 |
2018 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo.Clinical trials are warranted.
|
28397106 |
2017 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our study showed that the expressions of HER2, STAT3, and SOCS3 are associated with the progression of OC, and higher expressions of HER2 and STAT3 and lower expression of SOCS3 predict poor prognosis of OC.
|
28448787 |
2017 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression.
|
28265738 |
2017 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of HER2 codon 655 polymorphism with ovarian cancer.
|
26666819 |
2016 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 (HER2/ERBB2) gene amplification is associated with benefit from taxane therapy in breast cancer yet high HER2 expression also correlates with poor survival in both breast and ovarian cancer.
|
25602630 |
2015 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that HER2 represents an important oncogene in ovarian cancer, and suggest that targeting this tyrosine kinase with T-DM1 may be therapeutically effective, especially in ovarian tumors with high content of HER2.
|
26336133 |
2015 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review will trace the development of anti-HER2 therapies in breast and ovarian cancer.
|
26597460 |
2015 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Further, when tested in vivo in a HER-2-overexpressing ovarian cancer xenograft mouse model, enzymatically generated trastuzumab-maytansine was found to lead to complete regression of established tumors, similar to Kadcyla.
|
26132162 |
2015 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Herein, we illustrate a fairly new near infrared (NIR) optical imaging approach developed in our laboratory for the noninvasive detection of ovarian tumors using a HER-2 targeted nanoparticle-based imaging agent in an orthotopic mouse model of ovarian cancer.
|
25308269 |
2015 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the potential prognostic value of SKP2, genes P27Kip1, K-ras, c-Myc, COX2 and HER2 genes expression in ovarian cancer.
|
26320455 |
2015 |